Last week, Spotlight-listed Cereno Scientific published its report for the first quarter. The company’s CEO Sten R Sörensen, visited BioStock’s studio and talked about the preparations for the upcoming phase II trial, and how their international network and collaborations have resulted in two preclinical development programmes, and what awaits the company in the near term. Watch the full interview in Swedish below.
Watch the full interview with Cereno Scientific’s CEO Sten R Sörensen in the link below.
The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.